![Screenshot 2021-04-12 at 10.46.20 AM](https://antiguanewsroom.com/wp-content/uploads/2021/04/Screenshot-2021-04-12-at-10.46.20-AM-696x386.png)
Russia’s Sputnik V has been deemed to be safe, and works in a way similar to the Oxford-AstraZeneca jab which is being made in India as Covishield.
Sputnik V gives around 92% protection against Covid-19, late stage trial results published in The Lancet reveal.
Sputnik V’s approval came as India overtook Brazil to become the country with the second-highest number of cases globally.
India aims to vaccinate 250 million “priority people” by the end of July. But experts say that the pace of vaccination has been slow and unless the drive is scaled up, the target could be missed.
This means that vaccines made by Pfizer and Moderna could become available for Indians. However, the government is yet to give any details.
Antigua and Barbuda Becomes 57th Country to Register Russia’s Sputnik V Vaccine
What do we know about Sputnik V?
The vaccine, developed by Moscow’s Gamaleya Institute, initially generated some controversy after being rolled out before the final trial data had been released.
But scientists say its benefits have now been demonstrated.
It uses a cold-type virus, engineered to be harmless, as a carrier to deliver a small fragment of the coronavirus to the body.
Safely exposing the body to a part of the virus’s genetic code in this way allows it to recognise the threat and learn to fight it off, without the risk of becoming ill.
After being vaccinated, the body starts to produce antibodies especially tailored to the coronavirus.
This means that the immune system is primed to fight coronavirus when it encounters it for real.
It can be stored at temperatures of between 2 and 8C degrees (a standard fridge is roughly 3-5C degrees) making it easier to transport and store.
But it has a different second dose
Unlike other similar vaccines, the Sputnik jab uses two slightly different versions of the vaccine for the first and the second dose – given 21 days apart.
They both target the coronavirus’s distinctive “spike”, but use different vectors – the neutralised virus that carries the spike to the body.
The idea is that using two different formulas boosts the immune system even more than using the same version twice – and may give longer-lasting protection.
As well as proving effective, it was also safe with no serious reactions linked to the vaccine during the trial.
Some side-effects to a vaccine are expected, but these are usually mild, including a sore arm, tiredness and a bit of a temperature. There were no deaths or serious illnesses in the vaccinated group linked to the jab.
Sputnik V has been approved so far in 60 countries, including Argentina, Palestinian territories, Venezuela, Hungary, UAE and Iran.
When will Sputnik V be available in India?
The Russian Direct Investment Fund (RDIF), which is marketing the vaccine, has signed deals to produce more than 750 million doses of Sputnik V in India with six domestic vaccine makers, according to reports.
Hyderabad-based pharmaceutical major Dr Reddy’s Laboratories will be importing the first batch of 125 million doses to India during this quarter.
Supplies will be ramped up only next quarter when six Indian firms begin making the vaccine under the supervision of Dr Reddy’s.
Until then, India will mostly depend on two previously approved candidates, Covaxin and Covishield.
Advertise with the mоѕt vіѕіtеd nеwѕ ѕіtе іn Antigua!
We offer fully customizable and flexible digital marketing packages.
Contact us at [email protected]